450
Participants
Start Date
August 10, 2017
Primary Completion Date
March 31, 2026
Study Completion Date
June 30, 2026
Sevoflurane
Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
Remifentanil
Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
Dexmedetomidine
Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
Sydney Children's Hospital, Randwick
Children's Hospital at Westmead, Westmead
Royal Children's Hospital, Parkville
Queensland Children's Hospital, Brisbane
Women's and Children's Hospital, Adelaide
Flinders Medical Centre, Bedford Park
Perth Children's Hospital, Perth
The Children's Hospital of Philadelphia, Philadelphia
Cleveland Clinic, Cleveland
The University of Texas Southwestern Medical Center, Dallas
Texas Children's Hospital, Houston
Boston Children's Hospital, Boston
Presidio Ospedale Infantile C.Arrigo Azienda Ospedaliera, Alessandria
Azienda ospedaliero-universitaria di Bologna, Bologna
Azienda Ospedaliero-Universitaria Meyer, Florence
Istituto Giannina Gaslini, Genova
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico - Clinica Mangiagalli, Milan
Vittore Buzzi Children's Hospital, Milan
Azienda Ospedaliero Universitaria Pisana, Pisa
Ospedale Bambino Gesù, Roma
La Paz University Hospital, Madrid
Lead Sponsor
Collaborators (1)
Sydney Children's Hospitals Network
OTHER
Baylor College of Medicine
OTHER
Boston Children's Hospital
OTHER
The Cleveland Clinic
OTHER
University of Texas, Southwestern Medical Center at Dallas
OTHER
Royal Children's Hospital
OTHER
Children's Hospital of Philadelphia
OTHER
Queensland Children's Hospital
OTHER_GOV
Perth Children's Hospital
UNKNOWN
Women and Children's Hospital
UNKNOWN
Istituto Giannina Gaslini
OTHER
Flinders Medical Centre
OTHER_GOV
Murdoch Childrens Research Institute
OTHER